

**Date:** September 02, 2025

To,  
The Manager- Listing Department,  
**National Stock Exchange of India Limited,**  
Exchange Plaza, Plot No. C/1, Block-G,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051

**SYMBOL: REMUS**

Dear Sir/Madam,

**Sub: Intimation of Schedule of Analyst / Institutional Investor meetings under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015**

Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we would like to inform you that the officials of the Company will be interacting with the Investors (Participants) as per below details:

| Date & Time  | Organized by     | Nature of Meeting | Mode of Meeting |
|--|------------------|-------------------|-----------------|
| 11 <sup>th</sup> September, 2025<br>04:00 PM (IST) | Valorem Advisors | Group meeting     | Virtual         |

Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the meeting.

The Investor Presentation is available on the website of the Company viz. [www.remuspharma.com](http://www.remuspharma.com).

Kindly note that changes in the above schedule may happen due to exigencies on the part of Participants/ Company.

You are requested to take the same on record.

Thanking you.

**For, Remus Pharmaceuticals Limited**

**Deval Patel**  
Company Secretary and Compliance Officer  
ICSI Membership No.: A60090

Encl.: As above

## **Remus Pharmaceuticals Limited**

**REGISTERED OFFICE:** 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,  
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.  
P: 079 2999 9857

E. [remus@remuspharma.com](mailto:remus@remuspharma.com) | W. [www.remuspharma.com](http://www.remuspharma.com)  
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

# VALOREM CXO MEET

**Thursday, 11<sup>th</sup> September 2025 at 4:00 pm IST**

From the IR House that has brought you some of the most innovative and largest investor relation events, Valorem Advisors invites you to the virtual event: **Valorem CXO Meet**.

The Valorem CXO Meet will host Directors/CXO's from corporates over a virtual platform in a well-organized and structured manner, where management will discuss the company's growth journey and provide insights into the industry, operations, performance, vision, strategy, and also address various questions from the investor community.



**Remus Pharmaceuticals Ltd.**

Click on logo for the investor kit link

**4:00 pm IST**



**Mr. Arpit Shah**  
Managing Director



**Ms. Anjali Shah**  
Chief Financial Officer

## ABOUT

Remus Pharmaceuticals Ltd., established in 2015, is among the fastest-growing pharmaceutical companies, specializing in the branding, marketing, and distribution of complex specialty and niche off-patent formulations across global markets. Operating on an asset-light model, the company follows a quick go-to-market strategy by identifying high-potential off-patent drugs, conducting R&D, and filing dossiers in relevant countries.

The company's diversified portfolio includes 620+ approved products, 640+ under evaluation, and 745+ dossier registrations across major geographies. Its therapeutic coverage spans oncology, cardiology, dermatology, diabetes, and other key segments, complemented by niche formulations. Remus partners with over 30 global CDMO/CMO manufacturers holding required international accreditations. It has built a robust international footprint with a strong presence in 40+ semi-regulated and emerging markets through local distributors and direct subsidiaries in Bolivia and Guatemala.

In 2024, Remus entered the U.S. market via the acquisition of Espee Global Holdings LLC, one of the largest distributors of Reference Listed Drugs (RLDs). Espee specializes in sourcing and supplying hard-to-access REMS, specialty, orphan, and biosimilar drugs, serving 300+ customers across 30+ countries through its FDA-approved facility.

Remus Pharmaceuticals delivered a 3 Year CAGR for Revenue of 191% and 49%, on consolidated and standalone basis respectively, with healthy profitability and return ratios supported by low leverage.

**zoom**

**Register Here**

### Agenda:

- Management Journey
- Industry Overview
- Business and Operational Overview
- Financial Highlights
- Future Growth Strategy
- Q&A

### Rules:

- Pre-registration required to get zoom meeting invite
- All participants video and audio will be in switched off mode
- Participants can pre-request their questions in registration form or ask during the meeting in zoom chat